Leif Stenke

Publications
CV
Public outreach and news

Articles

Article: LEUKEMIA. 2024;38(4):781-787
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial
Flygt H; Soederlund S; Richter J; Saussele S; Koskenvesa P; Stenke L; Mustjoki S; Dimitrijevic A; Stentoft J; Majeed W; Roy L; Wolf D; Dreimane A; Gjertsen BT; Gedde-Dahl T; Ahlstrand E; Markevaern B; Hjorth-Hansen H; Janssen J; Olsson-Stroemberg U
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(4):644-654
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
Larfors G; Andersson P; Jesson G; Liljebris C; Brisander M; Lennernas H; Stenke L
Article: BLOOD. 2023;142(1):73-89
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Article: ONCOIMMUNOLOGY. 2022;11(1):2109861
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+CML stem/progenitor cells potentially through the upregulation of multiple key survival factors
Ujvari D; Malyukova A; Zovko A; Yektaei-Karin E; Madapura HS; Keszei M; Nagy N; Lotfi K; Bjorn N; Wallvik J; Stenke L; Salamon D
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2022;179(19):4709-4721
The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis
Carracedo M; Pawelzik S-C; Artiach G; Pouwer MG; Plunde O; Saliba-Gustafsson P; Ehrenborg E; Eriksson P; Pieterman E; Stenke L; Princen HMG; Franco-Cereceda A; Back M
Article: JOURNAL OF CLINICAL INVESTIGATION. 2022;132(17):e152585
IFN-a with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
Huuhtanen J; Ilander M; Yadav B; Dufva OMJ; Lahteenmaki H; Kasanen T; Klievink J; Olsson-Stromberg U; Stentoft J; Richter J; Koskenvesa P; Hoglund M; Soderlund S; Dreimane A; Porkka K; Gedde-Dahl T; Gjertsen BT; Stenke L; Myhr-Eriksson K; Markevarn B; Lubking A; Dimitrijevic A; Udby L; Bjerrum OW; Hjorth-Hansen H; Mustjoki S
Article: CELL DEATH DISCOVERY. 2022;8(1):284
Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
Haag P; Olsson M; Forsberg J; Lindberg ML; Stenerlow B; Zong D; Kanter L; Lewensohn R; Viktorsson K; Zhivotovsky B; Stenke L
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2022;97(4):421-430
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
Dahlen T; Edgren G; Ljungman P; Flygt H; Richter J; Olsson-Stromberg U; Wadenvik H; Dreimane A; Myhr-Eriksson K; Zhao J; Sjalander A; Hoglund M; Stenke L
Article: JOURNAL OF RADIOLOGICAL PROTECTION. 2022;42(1):014004
The acute radiation syndrome-need for updated medical guidelines
Stenke L; Hedman C; Lindberg ML; Lindberg K; Valentin J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;107(6):617-623
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
Flygt H; Soderlund S; Stentoft J; Richter J; Koskenvesa P; Mustjoki S; Majeed W; Lubking A; Dreimane A; Markevarn B; Stenke L; Myhr Eriksson K; Gjertsen BT; Gedde-Dahl T; Dimitrijevic A; Udby L; Olsson-Stromberg U; Hjorth-Hansen H
Article: CELL DEATH & DISEASE. 2021;12(10):875
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
Malyukova A; Ujvari D; Yektaei-Karin E; Zovko A; Madapura HS; Keszei M; Nagy N; Lotfi K; Bjorn N; Wallvik J; Tamai M; Nguyen TTT; Akahane K; Inukai T; Stenke L; Salamon D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):915-921
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
Flygt H; Sandin F; Dahlen T; Dremaine A; Lubking A; Markevarn B; Myhr-Eriksson K; Olsson K; Olsson-Stromberg U; Sjalander A; Soderlund S; Wennstrom L; Wadenvik H; Stenke L; Hoglund M; Richter J
Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2020;29(1):151-156
Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case-Control Study
Larfors G; Richter J; Sjalander A; Stenke L; Hoglund M
Article: BONE MARROW TRANSPLANTATION. 2019;54(11):1764-1774
Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry
Lubking A; Dreimane A; Sandin F; Isaksson C; Markevarn B; Brune M; Ljungman P; Lenhoff S; Stenke L; Hoglund M; Richter J; Olsson-Stromberg U
Article: ONCOIMMUNOLOGY. 2019;8(9):e1638210
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Kreutzman A; Yadav B; Brummendorf TH; Gjertsen BT; Hee ML; Janssen J; Kasanen T; Koskenvesa P; Lofti K; Markevarn B; Olsson-Stromberg U; Stentoft J; Stenke L; Soderlund S; Udby L; Richter J; Hjorth-Hansen H; Mustjoki S
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(4):555-567
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlen T; Lipton JH
Article: ONCOLOGY REPORTS. 2018;40(2):902-908
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis
Zovko A; Yektaei-Karin E; Salamon D; Nilsson A; Wallvik J; Stenke L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2018;498(3):502-508
Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells
Ujvari D; Nagy N; Madapura HS; Kallas T; Krohnke MCL; Stenke L; Klein E; Salamon D
Article: LAKARTIDNINGEN. 2017;114:ER3M
[Chronic myeloid leukemia – a model disease for targeted therapy].
Richter J; Stenke L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2017;490(2):378-384
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 ⁺CD38^- stem and progenitor cells in chronic myeloid leukemia
Dolinska M; Piccini A; Wong WM; Gelali E; Johansson A-S; Klang J; Xiao P; Yektaei-Karin E; Stromberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
Article: ONCOGENE. 2017;36(32):4619-4628
Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells
Madapura HS; Nagy N; Ujvari D; Kallas T; Krohnke MCL; Amu S; Bjorkholm M; Stenke L; Mandal PK; McMurray JS; Keszei M; Westerberg LS; Cheng H; Xue F; Klein G; Klein E; Salamon D
Article: LEUKEMIA & LYMPHOMA. 2017;58(8):1903-1913
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
Yektaei-Karin E; Zovko A; Nilsson A; Nasman-Glaser B; Kanter L; Radmark O; Wallvik J; Ekblom M; Dolinska M; Qian H; Stenke L
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2017;143(8):1543-1554
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
Rajala HLM; El Missiry M; Ruusila A; Koskenvesa P; Bruemmendorf TH; Gjertsen BT; Janssen J; Lotfi K; Markevarn B; Olsson-Stromberg U; Stenke L; Stentoft J; Richter J; Hjorth-Hansen H; Kreutzman A; Mustjoki S
Article: HAEMATOLOGICA. 2017;102(8):1361-1367
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
Gullaksen S-E; Skavland J; Gavasso S; Tosevski V; Warzocha K; Dumrese C; Ferrant A; Gedde-Dahl T; Hellmann A; Janssen J; Labar B; Lang A; Majeed W; Mihaylov G; Stentoft J; Stenke L; Thaler J; Thielen N; Verhoef G; Voglova J; Ossenkoppele G; Hochhaus A; Hjorth-Hansen H; Mustjoki S; Sopper S; Giles F; Porkka K; Wolf D; Gjertsen BT
Article: LEUKEMIA. 2017;31(5):1108-1116
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
Ilander M; Olsson-Stromberg U; Schlums H; Guilhot J; Bruck O; Lahteenmaki H; Kasanen T; Koskenvesa P; Soderlund S; Hoglund M; Markevarn B; Sjalander A; Lotfi K; Dreimane A; Lubking A; Holm E; Bjoreman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon F-X; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Article: BLOOD. 2017;129(17):2384-2394
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Stromberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(4):398-406
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia
Larfors G; Sandin F; Richter J; Sjalander A; Stenke L; Lambe M; Hoglund M
Article: PLOS ONE. 2017;12(1):e0171041
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
El Missiry M; Hjorth-Hansen H; Richter J; Olson-Stromberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(1):57-66
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
Soderlund S; Dahlen T; Sandin F; Olsson-Stromberg U; Creignou M; Dreimane A; Lubking A; Markevarn B; Sjalander A; Wadenvik H; Stenke L; Richter J; Hoglund M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;97(4):387-392
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence
Gunnarsson N; Sandin F; Hoglund M; Stenke L; Bjorkholm M; Lambe M; Olsson-Stromberg U; Richter J; Sjalander A
Article: LEUKEMIA. 2016;30(9):1853-1860
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
Hjorth-Hansen H; Stentoft J; Richter J; Koskenvesa P; Hoeglund M; Dreimane A; Porkka K; Gedde-Dahl T; Gjertsen BT; Gruber FX; Stenke L; Eriksson KM; Markevarn B; Lubking A; Vestergaard H; Udby L; Bjerrum OW; Persson I; Mustjoki S; Olsson-Stromberg U
Article: CLINICAL CANCER RESEARCH. 2016;22(16):4030-4038
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen B-T; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
Article: ANNALS OF INTERNAL MEDICINE. 2016;165(3):161-166
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia A Population-Based Cohort Study
Dahlen T; Edgren G; Lambe M; Hoglund M; Bjorkholm M; Sandin F; Sjalander A; Richter J; Olsson-Stromberg U; Ohm L; Back M; Stenke L
Article: LEUKEMIA. 2016;30(7):1562-1567
Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
Gunnarsson N; Hoglund M; Stenke L; Wallberg-Jonsson S; Sandin F; Bjorkholm M; Dreimane A; Lambe M; Markevarn B; Olsson-Stromberg U; Wadenvik H; Richter J; Sjalander A
Article: LANCET ONCOLOGY. 2016;17(5):612-621
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(5):683-688
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
Gunnarsson N; Stenke L; Hoglund M; Sandin F; Bjorkholm M; Dreimane A; Lambe M; Markevarn B; Olsson-Stromberg U; Richter J; Wadenvik H; Wallvik J; Sjalander A
Article: LEUKEMIA & LYMPHOMA. 2015;56(5):1385-1391
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
Ohm L; Lundqvist A; Dickman P; Hoglund M; Persson U; Stenke L; Carlsson KS; Bjorkholm M
Article: MOLECULAR CANCER THERAPEUTICS. 2015;14(5):1181-1191
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Christiansson L; Soderlund S; Mangsbo S; Hjorth-Hansen H; Hoglund M; Markevarn B; Richter J; Stenke L; Mustjoki S; Loskog A; Olsson-Stromberg U
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(3):243-250
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
Hjorth-Hansen H; Stenke L; Soderlund S; Dreimane A; Ehrencrona H; Gedde-Dahl T; Gjertsen BT; Hoglund M; Koskenvesa P; Lotfi K; Majeed W; Markevarn B; Ohm L; Olsson-Stromberg U; Remes K; Suominen M; Simonsson B; Porkka K; Mustjoki S; Richter J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(3):559-564
Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy
Othus M; Appelbaum FR; Petersdorf SH; Kopecky KJ; Slovak M; Nevin T; Brandwein J; Larson RA; Stiff PJ; Walter RB; Tallman MS; Stenke L; Erba HP
Article: CANCER CELL. 2014;26(3):428-442
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernandez-Boluda J-C; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon F-X; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
Article: BLOOD. 2013;122(7):1284-1292
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Hoglund M; Sandin F; Hellstrom K; Bjoreman M; Bjorkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevarn B; Myhr-Eriksson K; Ohm L; Olsson-Stromberg U; Sjalander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Article: CANCER. 2013;119(16):3076-3083
Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity
Patel C; Stenke L; Varma S; Lindberg ML; Bjorkholm M; Sjoberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM; Gillet J-P
Article: LEUKEMIA. 2013;27(7):1520-1526
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevarn B; Olofsson T; Olsson-Stromberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H
Article: BLOOD. 2013;121(24):4854-4860
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
Article: EXPERIMENTAL HEMATOLOGY. 2012;40(11):906-913.e1
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia
Kreutzman A; Jaatinen T; Greco D; Vakkila E; Richter J; Ekblom M; Hjorth-Hansen H; Stenke L; Melo T; Paquette R; Seggewiss-Bernhardt R; Guerci-Bresler A; Talbot A; Cayuela JM; Mahon F-X; Porkka K; Lipton J; Partanen J; Rousselot P; Mustjoki S
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2012;87(8):760-765
Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome
Ohm L; Arvidsson I; Barbany G; Hast R; Stenke L
Article: LEUKEMIA. 2011;25(10):1587-1597
Expansion of highly differentiated CD8⁺ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Article: LANCET ONCOLOGY. 2011;12(9):841-851
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh Y-T; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Article: BLOOD. 2010;116(5):772-782
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Article: LEUKEMIA. 2009;23(8):1398-1405
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Hoglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Article: EXPERIMENTAL HEMATOLOGY. 2009;37(6):755-766
Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
Haag P; Viktorsson K; Lindberg ML; Kanter L; Lewensohn R; Stenke L
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(6):2332-2341
Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia
Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtio J
Article: LEUKEMIA & LYMPHOMA. 2006;47(9):1768-1773
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy plus G-CSF in patients with chronic myelogenous leukemia in first chronic phase
Olsson-Stromberg U; Hoglund M; Bjorkholm M; Braide I; Carlson K; Gahrton G; Grimfors G; Hast R; Lerner R; Linder O; Ljungman P; Lofvenberg E; Malm C; Nilsson P-G; Paul C; Rodjer S; Stenke L; Tidefeldt U; Turesson I; Uden A-M; Wahlin A; Vilen L; Winqvist I; Zettervall O; Oberg G; Simonsson B
Article: ACTA HAEMATOLOGICA. 2005;113(3):155-162
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia:: Long-term follow-up
Simonsson B; Öberg G; Björeman M; Björkholm M; Carneskog J; Karlsson K; Gahrton G; Grimfors G; Hast R; Karle H; Linder O; Ljungman P; Nielsen JL; Nilsson J; Löfvenberg E; Malm C; Olsson K; Olsson-Strömberg U; Paul C; Stenke L; Stentoft J; Turesson I; Udén AM; Wahlin A; Vilén L; Weis-Bjerrum O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(6):739-745
Abnormal LTC₄ synthase RNA degradation in neutrophils from CML patients
Roos C; Sjölinder M; Stenke L; Tornhamre S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2004;350(2):114-124
Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T; European Collaboration on Low-Dose Aspirin in Poly
Article: LEUKEMIA RESEARCH. 2003;27(4):323-328
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
Gruber A; Björkholm M; Brinch L; Evensen S; Gustavsson B; Hedenus M; Juliusson G; Löfvenberg E; Nesthus I; Simonsson B; Sjo M; Stenke L; Tangen JM; Tidefelt U; Udén AM; Paul C; Liliemark J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2003;348(11):994-1004
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ; IRIS Investigators
Article: EXPERIMENTAL HEMATOLOGY. 2003;31(2):122-130
Inverse relationship between myeloid maturation and leukotriene C₄ synthase expression in normal and leukemic myelopoiesis -: consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia
Tornhamre S; Stenke L; Granzelius A; Sjölinder M; Näsman-Glaser B; Roos C; Widell S; Lindgren J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;118(4):1048-1054
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase -: a report from the Swedish CML Group
Axdorph U; Stenke L; Grimfors G; Carneskog J; Hansen J; Linder O; Ljungman P; Löfvenberg E; Malm C; Simonsson B; Turesson I; Vilén L; Udén AM; Björkholm M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;118(3):748-754
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia
Hallböök H; Simonsson B; Ahlgren T; Björkholm M; Carneskog J; Grimfors G; Hast R; Karlsson K; Kimby E; Lerner R; Linder O; Linderholm M; Löfvenberg E; Malm C; Nilsson PG; Paul C; Stenke L; Stockelberg D; Tidefelt U; Turesson I; Uden-Blome AM; Vilen L; Wahlin A; Winquist I; Smedmyr B
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(6):376-381
Long-term follow-up of patients ≥60 yr old with acute myeloid leukaemia treated with intensive chemotherapy
Öberg G; Killander A; Björeman M; Gahrton G; Grimfors G; Gruber A; Hast R; Lerner R; Liliemark J; Mattson S; Paul C; Simonsson B; Stalfelt AM; Stenke L; Tidefelt U; Udén AM; Björkholm M
Article: LAKARTIDNINGEN. 2002;99(13):1453-1455
[Management of radiation injuries--new organization, new guidelines].
Lewensohn R; Joussineau S; Stenke L
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(3):180-186
Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Article: LEUKEMIA RESEARCH. 2001;25(1):13-18
Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment
Hast R; Wallvik J; Folin A; Bernell P; Stenke L
Article: JOURNAL OF CLINICAL ONCOLOGY. 2000;18(9):1837-1844
P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia
Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
Article: BLOOD. 2000;95(4):1456-1464
Aberrant expression of active leukotriene C₄ synthase in CD16⁺ neutrophils from patients with chronic myeloid leukemia
Sjölinder M; Stenke L; Näsman-Glaser B; Widell S; Doucet J; Jakobsson PJ; Lindgren J
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 1998;64(2):228-234
Expression of mRNA encoding neurotrophins and neurotrophin receptors in human granulocytes and bone marrow cells -: enhanced neurotrophin-4 expression induced by LTB₄
Laurenzi MA; Beccari T; Stenke L; Sjölinder M; Stinchi S; Lindgren J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1998;101(4):728-736
Novel enzymatic abnormalities in AML and CML in blast crisis:: elevated leucocyte leukotriene C₄ synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrate
Stenke L; Sjölinder M; Miale TD; Lindgren J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(4):241-245
Differences in cell lineage involvement between MDS-AML and de novo AML studied by fluorescence in situ hybridization in combination with morphology
Bernell P; Arvidsson I; Hast R; Jacobsson B; Stenke L
Article: LEUKEMIA RESEARCH. 1996;20(8):693-699
A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes
Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1995;55(1):19-23
MITOXANTRONE, ETOPOSIDE AND ARA-C VS DOXORUBICIN-DNA, ARA-C, THIOGUANINE, VINCRISTINE AND PREDNISOLONE IN THE TREATMENT OF PATIENTS WITH ACUTE MYELOCYTIC-LEUKEMIA - A RANDOMIZED COMPARISON
BJORKHOLM M; LILIEMARK J; GAHRTON G; GRIMFORS G; GRUBER A; HAST R; JULIUSSON G; JARNMARK M; KILLANDER A; KIMBY E; LERNER R; LJUNGMAN P; LONNQVIST B; PALMBLAD J; PAUL C; PETTERSON C; SIMONSSON B; STALFELT AM; STENKE L; SUNDSTROM C; TIDEFELT U; UDEN AM; OBERG G; OST A
Show more

All other publications

Corrigendum: LEUKEMIA. 2024;38(4):925
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H; Söderlund S; Richter J; Saussele S; Koskenvesa P; Stenke L; Mustjoki S; Dimitrijevic A; Stentoft J; Majeed W; Roy L; Wolf D; Dreimane A; Gjertsen BT; Gedde-Dahl T; Ahlstrand E; Markevärn B; Hjorth-Hansen H; Janssen J; Olsson-Strömberg U
Letter: LEUKEMIA. 2023;37(5):1156-1159
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study
Dahlen T; Flygt H; Lubking A; Olsson-Stromberg U; Wennstrom L; Dreimane A; Sjalander A; Leach S; Gisslen M; Li H; Hoglund M; Stenke L; Nyberg F
Editorial comment: JOURNAL OF RADIOLOGICAL PROTECTION. 2022;42(3):030202
To be (prepared) or not to be-that is hardly the question
Valentin J; Stenke L
Review: JOURNAL OF RADIOLOGICAL PROTECTION. 2022;42(3):031001
Mental health and psychosocial consequences linked to radiation emergencies-increasingly recognised concerns
Lagergren Lindberg M; Hedman C; Lindberg K; Valentin J; Stenke L
Letter: LEUKEMIA. 2021;35(8):2416-2418
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
Richter J; Lubking A; Soderlund S; Lotfi K; Markevarn B; Sjalander A; Stenke L; Deneberg S; Ahlstrand E; Myhr-Eriksson K; Panayiotidis P; Gedde-Dahl T; Zackova D; Mayer J; Olsson-Stromberg U; Mahon F-X; Saussele S; Hjorth-Hansen H; Koskenvesa P
Editorial comment: JACC: CARDIOONCOLOGY. 2020;2(1):123-126
Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
Carracedo M; Stenke L; Franco-Cereceda A; Back M
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2018;182(1):80-84
COORDINATION OF MANAGEMENT OF THE ACUTE RADIATION SYNDROME
Stenke L; Lindberg K; Lindberg ML; Lewensohn R; Valentin J; Powles R; Dainiak N
Letter: LEUKEMIA. 2017;31(8):1825-1827
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden
Gunnarsson N; Hoglund M; Stenke L; Sandin F; Bjorkholm M; Dreimane A; Lambe M; Markevarn B; Olsson-Stromberg U; Wadenvik H; Richter J; Sjalander A
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2016;171(1):134-138
Lessons Learnt from the Fukushima Accident-A Swedish Medical Preparedness Perspective
Stenke L; von Schreeb J; Simonsson M; Johansson J; Postgard P; Sigurdsson S; Ljungquist A; Lindberg ML
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2016;171(1):144-155
Using the Grade Approach to Support the Development of Recommendations for Public Health Interventions in Radiation Emergencies
Carr Z; Clarke M; Akl EA; Schneider R; Murith C; Li C; Parrish-Sprowl J; Stenke L; Cui-Ping L; Bertrand S; Miller C
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(25):2821-2823
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
Richter J; Soderlund S; Lubking A; Dreimane A; Lotfi K; Markevarm B; Sjalander A; Saussele S; Olsson-Stromberg U; Stenke L
Review: DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS. 2011;5(3):183-201
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems.
Dainiak N; Gent RN; Carr Z; Schneider R; Bader J; Buglova E; Chao N; Coleman CN; Ganser A; Gorin C; Hauer-Jensen M; Huff LA; Lillis-Hearne P; Maekawa K; Nemhauser J; Powles R; Schünemann H; Shapiro A; Stenke L; Valverde N; Weinstock D; White D; Albanese J; Meineke V
Review: DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS. 2011;5(3):202-212
First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation
Dainiak N; Gent RN; Carr Z; Schneider R; Bader J; Buglova E; Chao N; Coleman CN; Ganser A; Gorin C; Hauer-Jensen M; Huff LA; Lillis-Hearne P; Maekawa K; Nemhauser J; Powles R; Schuenemann H; Shapiro A; Stenke L; Valverde N; Weinstock D; White D; Albanese J; Meineke V
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(5):57
Cytotoxicity and cell death signaling in stem cell like AML cells
Haag P; Lindberg ML; Zong D; Kanter L; Lewensohn R; Stenke L; Viktorsson K
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(5):134-135
The DNA glycosylase Myh1 is stabilized by cisplatin and inhibition of Myh1 expression increases cisplatin-induced apoptotic signaling in lung carcinoma cells
Viktorsson K; Efazat G; Haag P; Zong D; Stenke L; Sunnerhagen P; Lewensohn R
Letter: ANNALS OF HEMATOLOGY. 2009;88(2):173-175
Chronic myeloid leukemia presenting late in pregnancy. Report of a case and a questionnaire reflecting diversity in management options
Bjorkholm M; Ohm L; Stenke L
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2008;142(6):992-995
Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C₄ synthase expression and activity in chronic myeloid leukaemia
Roos C; Stenke L; Ohm L; Widell S; Kumlin M; Lindgren JA; Tornhamre S
Letter: LEUKEMIA. 2006;20(11):2057-2060
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib
Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
Meeting abstract: BLOOD. 2005;106(11):222B
Gemtuzumab ozogamicin combined with hyper-CVAD in relapsed refractory CD33-positive acute lymphoblastic leukemia.
Stromberg O; Stenke L; Bernell P
Meeting abstract: BLOOD. 2005;106(11):566A
Quantitative analyses of BCR-ABL mutations associated with imatinib treatment in CML
Gruber F; Hansen HH; Olsen M; Eggen L; Skogen B; Gedde-Dahl T; Lundan T; Porkka K; Simonsson B; Markevdrn B; Wadenvik H; Stenke L
Review: LAKARTIDNINGEN. 2000;97(3):164-167
[Radioimmunotherapy is rapidly developing to clinically efficient therapy].
Stenke L; Lewensohn R; Carlsson J
Show more

Employments

Professor Emeritus/Emerita, Department of Medicine, Karolinska Institutet, 2025-2025
Adjunct Professor, Department of Medicine, Karolinska Institutet, 2024-2024

Degrees and Education

Docent, KI., 1993

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI